119 related articles for article (PubMed ID: 3011442)
21. Nitric oxide regulation of TP receptor-mediated pulmonary vasoconstriction in the anesthetized, open-chest rat.
Valentin JP; Bessac AM; Maffre M; John GW
Eur J Pharmacol; 1996 Dec; 317(2-3):335-42. PubMed ID: 8997619
[TBL] [Abstract][Full Text] [Related]
22. Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo.
Fitzgerald DJ; Doran J; Jackson E; FitzGerald GA
J Clin Invest; 1986 Feb; 77(2):496-502. PubMed ID: 3003161
[TBL] [Abstract][Full Text] [Related]
23. Preservation of ischemic myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute myocardial infarction.
Hock CE; Ribeiro LG; Lefer AM
Am Heart J; 1985 Feb; 109(2):222-8. PubMed ID: 2981461
[TBL] [Abstract][Full Text] [Related]
24. Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet deposition in dogs with experimentally stenosed coronary arteries.
Golino P; Buja LM; Ashton JH; Kulkarni P; Taylor A; Willerson JT
Circulation; 1988 Sep; 78(3):701-11. PubMed ID: 3409505
[TBL] [Abstract][Full Text] [Related]
25. G619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, reduces myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion in rats.
Squadrito F; Ioculano M; Altavilla D; Zingarelli B; Canale P; Campo GM; Saitta A; Oriti S; Spignoli G; Caputi AP
Pharmacology; 1993 Sep; 47(3):167-75. PubMed ID: 8415867
[TBL] [Abstract][Full Text] [Related]
26. Protection of ischemic cat myocardium by CGS-13080, a selective potent thromboxane A2 synthesis inhibitor.
Burke SE; DiCola G; Lefer AM
J Cardiovasc Pharmacol; 1983; 5(5):842-7. PubMed ID: 6195474
[TBL] [Abstract][Full Text] [Related]
27. Effects of two nonsulfhydryl angiotensin-converting enzyme inhibitors, CGS 14831 and CGS 16617, on myocardial damage and left-ventricular hypertrophy following coronary artery occlusion in the rat.
Smith EF; Egan JW; Goodman FR; Zimmerman MB; Webb RL; Ribeiro LG
Pharmacology; 1988; 37(4):254-63. PubMed ID: 2973611
[TBL] [Abstract][Full Text] [Related]
28. Differential involvement of serotonin 2A/C and thromboxane A2/prostanoid receptors in high- vs. low-shear rate arterial thrombosis in rabbits.
Valentin JP; Vieu S; Bertolino F; Fauré P; John GW
J Pharmacol Exp Ther; 1997 Feb; 280(2):761-9. PubMed ID: 9023289
[TBL] [Abstract][Full Text] [Related]
29. Preservation of ischemic myocardium by pinane thromboxane A2.
Schrör K; Smith EF; Bickerton M; Smith JB; Nicolaou KC; Magolda R; Lefer AM
Am J Physiol; 1980 Jan; 238(1):H87-92. PubMed ID: 7356037
[TBL] [Abstract][Full Text] [Related]
30. Direct myocardial effects of the thromboxane A2/prostaglandin H2 agonists U-46619 and SQ 26,655 under ischemic and nonischemic conditions.
Grover GJ; Hedberg A; Ogletree ML
Pharmacology; 1990; 41(1):1-15. PubMed ID: 2122481
[TBL] [Abstract][Full Text] [Related]
31. Differences in activities of thromboxane A2 receptor antagonists in smooth muscle cells.
Miki I; Kase H; Ishii A
Eur J Pharmacol; 1992 Oct; 227(2):199-204. PubMed ID: 1426029
[TBL] [Abstract][Full Text] [Related]
32. Thromboxane contributes to submaximal coronary dilation during myocardial ischemia.
Eller BT; Brooks LA; Dellsperger KC
Microcirculation; 1995 Aug; 2(2):165-72. PubMed ID: 7497168
[TBL] [Abstract][Full Text] [Related]
33. Effects of ganglionic blockade on noradrenaline release and cell injury in the acutely ischemic rat myocardium.
Abrahamsson T; Almgren O; Holmgren S
J Cardiovasc Pharmacol; 1982; 4(4):584-91. PubMed ID: 6181332
[TBL] [Abstract][Full Text] [Related]
34. Inhibitory effect of KW-3049, a new 1,4-dihydropyridine calcium antagonist, on the reduction of myocardial creatine kinase activity and high-energy phosphate content in rats subjected to coronary artery ligation.
Karasawa A; Kubo K
J Pharmacobiodyn; 1988 Nov; 11(11):722-9. PubMed ID: 3236204
[TBL] [Abstract][Full Text] [Related]
35. Protective effect of the specific thromboxane receptor antagonist, BM-13505, in reperfusion injury following acute myocardial ischemia in cats.
Bhat AM; Sacks H; Osborne JA; Lefer AM
Am Heart J; 1989 Apr; 117(4):799-803. PubMed ID: 2929397
[TBL] [Abstract][Full Text] [Related]
36. Effect of thromboxane receptor blockade on oxygen supply/consumption variables during reperfusion in the anesthetized dog.
Grover GJ; Sleph PG; Weiss HR
J Pharmacol Exp Ther; 1990 Jun; 253(3):1097-102. PubMed ID: 2141635
[TBL] [Abstract][Full Text] [Related]
37. Protective action of a thromboxane synthetase inhibitor in preventing extension of infarct size in acute myocardial infarction.
Hock CE; Phillips GR; Lefer AM
Prostaglandins Leukot Med; 1985 Mar; 17(3):339-46. PubMed ID: 3857643
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
Golino P; Ashton JH; McNatt J; Glas-Greenwalt P; Yao SK; O'Brien RA; Buja LM; Willerson JT
Circulation; 1989 Apr; 79(4):911-9. PubMed ID: 2494005
[TBL] [Abstract][Full Text] [Related]
39. Cardioprotective actions of a new calcium channel blocker in acute myocardial ischemia.
Brezinski ME; Darius H; Lefer AM
Arzneimittelforschung; 1986 Mar; 36(3):464-6. PubMed ID: 3707665
[TBL] [Abstract][Full Text] [Related]
40. Glomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2 alpha, in the rat. Evidence for interaction with thromboxane A2 receptors.
Takahashi K; Nammour TM; Fukunaga M; Ebert J; Morrow JD; Roberts LJ; Hoover RL; Badr KF
J Clin Invest; 1992 Jul; 90(1):136-41. PubMed ID: 1386085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
